New digital tool aims to keep patients on Weight-Loss meds longer
NCT ID NCT07216651
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tested a web-based tool called WeDosify that helps doctors manage dosing of the weight-loss drug semaglutide for adults with overweight or obesity. Twenty participants who had recently started semaglutide used the tool over three months. The main goal was to see if the tool helped people stay on their medication without stopping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amarillo Premier Research (an Objective Health Partnership)
Amarillo, Texas, 37067, United States
Conditions
Explore the condition pages connected to this study.